Ranbaxy API Plant Given FDA Warning

Ranbaxy's active pharmaceutical ingredient (API) manufacturing factory in Toansa, Punjab has received a Form 483 warning from the US FDA, communicating concerns discovered during last week's inspection.

As Ranbaxy's main API factory, the Toansa facility supplies about 70% of the raw ingredients for production, including supplying to Ranbaxy's Ohm Laboratories plant in New Jersey.

Other India-based Ranbaxy factories — at Paonta Sahib (Himachal Pradesh), Dewas (Madhya Pradesh) and Mohali (Punjab) — are already barred from exporting drugs to the US.

In a press statement, Ranbaxy said it will assess the observations and respond to the FDA.

Read the Business Standard press release

More News:

All news »

What are your comments?

Join the discussion today. Login Here.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments